Top Markets
#1 DogBull DogBull +36.46%
#2 The Bitcoin Bull The Bitcoin Bull +31.37%
#3 Siacoin Siacoin +27.38%
#4 Merlin's Seal BTC Merlin's Seal BTC +25.80%
#5 Cash Cat Cash Cat +19.34%
#6 Ontology Gas Ontology Gas +18.55%
#7 MarsCoin MarsCoin +17.63%
#8 Pons Pons +17.48%
#9 Akedo Akedo +11.80%
#10 Uniswap Uniswap +11.35%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Lumosa Therapeutics Co., Ltd. Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd.

6535
Rank in Stocks #14758
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company,... Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Share Price
$2.35
Market Cap
$394.12M
Change (1 day)
-1.07%
Change (1 year)
-64.75%
Country
TW
Trade Lumosa Therapeutics Co., Ltd. (6535)

Category

Healthcare
Revenue for Lumosa Therapeutics Co., Ltd. (6535)
Revenue in Sep 2026 TTM: 0
According to Lumosa Therapeutics Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lumosa Therapeutics Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH